Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Broad-Spectrum Antiviral Therapeutics

Figure 9

DRACOs appeared promising when administered via intraperitoneal (i.p.) injection in proof-of-concept trials with adult BALB/c mice.

(A) 2.5 mg PTD-PKR-Apaf DRACO administered i.p. penetrated the liver, kidney, and lungs and persisted for at least 48 hours. Averages of 3 mice per data point are plotted, and error bars show s.e.m. (B) PTD-PKR-Apaf and TAT-PKR-Apaf DRACOs administered i.p. from day -1 through day 3 greatly reduced the morbidity and day-2 lung viral titers in mice challenged intranasally (i.n.) with 1.3 LD50 influenza H1N1 A/PR/8/34. (C) PTD-RNaseL-Apaf, TAT-RNaseL-Apaf, and ARG-RNaseL-Apaf DRACOs administered i.p. from day -1 through day 3 greatly reduced the morbidity and day-2 lung viral titers in mice challenged i.n. with 0.3 LD50 influenza H1N1 A/PR/8/34.

Figure 9

doi: https://doi.org/10.1371/journal.pone.0022572.g009